Improving outcomes for patients with osteosarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to collect high-quality clinical data and biological samples from patients diagnosed with osteosarcoma, a common bone cancer. By gathering information on disease characteristics, treatment responses, and patient demographics, the study seeks to enhance understanding of osteosarcoma biology. The collected blood and tissue samples will be analyzed in research laboratories to identify potential tumor markers and improve treatment strategies. The ultimate goal is to improve patient outcomes through better-informed clinical decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* New histological diagnosis of osteosarcoma or in the absence of osteoid seen on biopsy, pathology and imaging supportive of a diagnosis of osteosarcoma. (It is well recognised that some patients may present with features suggestive of osteosarcoma (under 40 years, radiological abnormality compatible) but in whom no osteoid is detected in needle biopsy. Although categorised as spindle cell tumour of bone, such patients are usually treated in an identical approach to osteosarcoma. A definite diagnosis of osteosarcoma is then often possible after surgery when the entire resection specimen is available.)
* Written informed consent of patient and/or parent/legal guardian.

Exclusion Criteria:

• Diagnosis more than four months prior to registration.

Where it's running

• University College Hospitals London NHS Foundation Trust
  London, Greater London, United Kingdom Recruiting
• NHS Grampian Health Board
  Aberdeen, United Kingdom Recruiting
• Birmingham Women's and Childrens NHS Foundation Trust
  Birmingham, United Kingdom Recruiting
• The Royal Orthopaedic Hospital NHS Foundation Trust
  Birmingham, United Kingdom Recruiting
• University Hospitals Birmingham NHS Foundation Trust
  Birmingham, United Kingdom Recruiting
• Cambridge University Hospitals NHS Foundation Trust
  Cambridge, United Kingdom Recruiting

Study contacts

• Principal investigator: Sandra Strauss, MD — University College Hospitals London
• Study coordinator: Krystyna Reczko
• Email: ctc.iconic@ucl.ac.uk
• Phone: 020 7679 9878

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

  This study tests mifamurtide added to standard chemotherapy versus standard treatment with sorafenib to see if the combination helps patients with high-risk osteosarcoma.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazovian · NCT07787429

• 68Ga-B7-H3 Nanobody PET Imaging in Osteosarcoma

  This study tests a new gallium-68 labeled B7-H3 nanobody to see if it can image osteosarcoma tumors more clearly.

  Recruiting Early Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07774533

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma

  This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07648069

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.